<DOC>
	<DOCNO>NCT02615782</DOCNO>
	<brief_summary>This study randomize , open-label , oral single dosing , two-way crossover clinical trial evaluate effect food bioavailability CKD-397 single oral dose healthy male subject</brief_summary>
	<brief_title>A Clinical Trial Evaluate Effects Food Bioavailability CKD-397 Healthy Male Subjects</brief_title>
	<detailed_description>To healthy male subject sixteen ( 16 ) , follow treatment administer dosing period wash-out period minimum 10 day . Treatment A : CKD-397 1T Fasting condition Treatment B : CKD-397 1T Fed condition ( high fat meal ) . Pharmacokinetic blood sample collect 72hrs . Safety pharmacokinetic assess .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1 . Healthy male subject old 19 year time screen . 2 . Subjects BMI 17.5kg/m2 less 30.5kg/m2 weight 55kg 3 . Subjects sign informed consent form understand fully hear detailed explanation clinical trial 1 . Subjects history blood , kidney , endocrine , respiratory , gastrointestinal , urinary , cardiovascular , hepatic , psychiatric , neurological allergic disease clinically significant ( Except untreated asymptomatic seasonal allergy time administration ) 2 . Subjects history gastrointestinal disease gastrointestinal surgery affect drug absorption . 3 . Subjects show AST AST &gt; 2 time upper limit normal range eGFR &lt; 60 mL/min/1.73m2 4 . Subjects drink Alcohol &gt; 210g/week within 6 month prior screen . 5 . Subjects take medication involve clinical trial bioequivalence test within three month first dose medication character . 6 . Subjects show Systolic Blood Pressure ≤100 ≥150 mmHg Diastolic Blood Pressure ≤60 ≥100 mmHg screen 7 . Subjects orthostatic hypotension 8 . Subjects history drug abuse drug abuse positive screen 9 . Subjects treat metabolize enzyme inducer inhibitor barbital within 30days prior first dosing . 10 . Smoker ( ≥ 20cigarettes/day ) 11 . Subjects take ETC herb medicine within two week OTC vitamin supplement within 1 week first IP administration 12 . Subjects whole blood donation within two month component blood donation within 1month prior first dose receive blood transfusion within 1month prior first dose 13 . Subjects increase risk due clinical test administration drug Severe grade / chronic medical , mental condition abnormal laboratory result may interfere analysis test result 14 . Subjects take organic nitrate medicine regularly intermittently 15 . Patients genetic degenerative retinal disease include retinitis pigmentosa 16 . Subjects hypersensitivity medicine include tadalafil/tamsulosin component medicine ( aspirin , antibiotic etc . ) medical history clinically significant hypersensitivity 17 . Patients lose sight one eye Nonarteritic anterior ischemic optic neuropathy ( NAION ) 18 . Subjects hereditary disease galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 19 . Subjects use trustworthy method contraception 20 . Subjects able comply guideline describe protocol 21 . Subjects determine investigator 's decision include laboratory test result another reason unsuitable clinical trial participation</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>